Launch Excellence 2035. Winning in an era of exponential change.

The medicine has not changed. The conditions for its success have.

A medicine can succeed scientifically and enter a market whose rules have changed. This exploration asks what happens when advances in discovery and R&D meet new decision systems, affordability constraints, competing care models, and AI-informed stakeholders. Ten forces are already in motion, and every future contains them. Four change what a medicine is and how it is judged; six change the market it enters.

The purpose is not to identify the most likely future. It is to reveal the choices a launch strategy built only around today’s market could miss. One interpretation runs through the report: more launches may need the diagnostic-led patient identification and subgroup evidence associated with rare disease, without inheriting rare-disease pricing or a bespoke commercial model.

The worlds diverge on authority and on money.

The driving forces are a given; the scope and speed with which they transform the biopharma model are not. From a large universe of further uncertainties, THRIVE selected the ten it expects to shape the commercial model most profoundly by 2035. Two of them frame the worlds: one concerns authority, the other concerns money. The other eight specify the conditions inside each world.

Four worlds. What would launch success depend on?

Algorithmic Order

System-governed · Paid for outcomes

The medicine works. Its place in the system is another question.

Much of U.S. care is organized through institutional pathways that connect diagnosis, treatment, and follow-up. Following the pathway is the default; a departure needs a documented reason. A material share of payment depends on results verified after treatment, and a medicine’s position and terms stay open to reassessment as evidence and alternatives evolve.

Three weeks after an alert, her treatment, transport, monitoring, and follow-up are arranged. She has read about a medicine that would mean fewer visits; the pathway does not support it for her profile. She is looked after. She has little say.

What launch success depends on. Pathway position, earned with evidence the pathway can ingest and continuously reassessed. Outcome ownership: a deliberate decision about which parts of the care that produce the result the company takes responsibility for, because payment depends on them.

The Waiting Room

System-governed · Paid by price and volume

The patient has been found. The money has not.

The system identifies treatable need earlier and more precisely, but payment stays tied to units at negotiated prices, and budgets and capacity do not expand as fast as the population now identified. Companies compete to make worthwhile treatment affordable for more people through better patient selection, credible lower-cost alternatives, simpler administration, or better use of existing care.

An AI read of a routine mammogram flags her risk two years early. She meets the clinical criteria, not the plan’s funded tier: eligible, not funded this cycle. Her sister, insured through a different employer, has already started the recommended medicine.

What launch success depends on. Benefit-based patient definition: showing where the incremental benefit is unmistakable before the payer draws the funded tier. Affordable-scale design: price, delivery model, and channel planned around the full identified population, with funded reach and capacity tested before launch.

Precision Islands

Distributed · Paid for outcomes

Prevention is organized. Treatment remains a personal choice.

Competing care networks organize prevention, treatment, and follow-up around results over time, and use performance-linked agreements where results can be measured reliably. Clinicians and patients keep meaningful choice. The best experience is not equally available: coverage, geography, and willingness to participate shape who gets it.

The nurse calls while she is walking her dog; her home readings have changed. She and her physician compare two covered options and choose one she can sustain. Her brother is just as willing to take part; neither plan available through his employer includes the network.

What launch success depends on. A package that travels: the medicine plus the diagnostics, monitoring, and support that produce the outcome, tailored to the targeted networks. Network sequencing: which networks to enter, in which order, and how to reduce contracting and deployment costs through reuse.

Many Doors

Distributed · Paid by price and volume

Care remains episodic. The sources of influence multiply.

Care remains predominantly episodic and transactional. Personal AI advisers, clinical tools, virtual services, employer programs, and membership offerings add sources of advice and routes to treatment; no organization routinely assembles them into continuous care. Medicines are paid for mainly through units at agreed net or cash prices, and the treatment decision stays with clinician and patient.

By Thursday she has three recommendations about switching medicines: her physician’s, her insurer’s, her adviser’s. She uploads her wearable summary, compares costs, and a manufacturer’s cash channel makes the switch affordable by Friday. The developer’s access dashboard has not moved.

What launch success depends on. Route economics: knowing which routes generate additional demand, which redistribute it, and what each contributes after costs. Coherence across advisers: one evidence-grounded value story, accurately represented in the physician’s tool, the patient’s adviser, and the care service.

Seven no-regret moves. Useful in every world.

Seven actions create value in all four worlds. They are recurring disciplines rather than an execution order, and they build the eight success factors before the market chooses which of them matters most. Each has an accountable owner and a concrete output in the report.

1. Rehearse, monitor, and adapt. Test current plans against all four worlds; connect signals to an accountable response.
2. Build evidence that earns trust. Answer meaningful clinical and value questions; map evidence to each decision it must support; stay explicit about uncertainty.
3. Build AEO and decision-system readiness. Learn on marketed products how AI tools represent the evidence, then carry accurate information and monitoring into launch.
4. Design access for affordable scale. Test price, delivery requirements, and reachable treatment together; hold an affordable-scale case beside the premium case.
5. Build with patients, not only for them. Let experience, burden, and access barriers shape the proposition.
6. Choose ecosystem roles and partners. Decide what the company will provide, who is responsible for the rest, and what continues when a patient or partner leaves.
7. Rehearse delivery and accountability. Test capacity and handoffs, assign decision rights, and reuse the learning across launches.

THRIVE Futures Architecture™. Scenario planning for decisions under deep uncertainty.

THRIVE Futures Architecture™ is our scenario planning method for decisions under deep uncertainty. It moves from what is given, the driving forces, to what is open, the critical uncertainties, to the two selected as axes, to the worlds those axes define, and then to the response for a specific decision-maker. The worlds are built so that a strategy or plan can be tested against each of them; the value lies in what holds across all four and in what only one world demands.

This edition takes the vantage of the launch leader and the launch excellence function. The same forces and uncertainties, read from regulatory, supply, medical, or a portfolio committee, would stress different uncertainties and demand different adaptations. THRIVE’s Futures of Biopharma work extends to those questions, and to care models and organizational capability. Europe and Asia editions follow later in Q4 2026.